Different ka and f [Power / Sample Size]

posted by sam – India, 2012-11-28 13:38 (4547 d 12:09 ago) – Posting: # 9615
Views: 16,669

Dear Helmut

It’s a nice Joke and I am very glad that I have added your joke in my memories.
Thanks for your nice and explanatory mail.
In case of the Fed study the ISCV is more than 30%. Based on that should I go for the partially or fully replicate design along with the reformulation.
Since this I am adding one more variable like partially replicate and fully replicate and second variable is reformulation. So I am bit doubtful will it be a wise decision to go with both the variables in a singly time to save the time lines.
Plz also suggest if this is really a highly variable drug product with some references, if possible.
Hope for the positive reply.

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
146 visitors (0 registered, 146 guests [including 9 identified bots]).
Forum time: 02:48 CEST (Europe/Vienna)

If you shut your door to all errors
truth will be shut out.    Rabindranath Tagore

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5